Its targeted approach and less frequent dosing may offer a simpler way to manage HAE, especially for people who experience sudden and painful flare-ups despite treatments.
Why Was It Approved?
Dawnzera was approved because clinical studies showed that it was safe, well tolerated, and effective in reducing the number and severity of HAE attacks.
The reduction of attacks from baseline was 90% in those who received Dawnzera every four weeks, 83% with Dawnzera every eight weeks, and 16% in the placebo group.
In a longer-term study, people who took Dawnzera every eight weeks continued to have fewer attacks. Those who switched from other long-term HAE treatments to Dawnzera saw a 62% drop in attack frequency over 16 weeks, with no increase in flare-ups. Most people who made the switch said they preferred Dawnzera because it gave them better control of their condition, was easier to use, and caused less pain or reactions where it was injected. The most common side effects were mild and included redness, swelling, or itching where the shot was given. Some people also had upper airway infections, urinary tract infections, or stomach discomfort. Serious allergic reactions, including anaphylaxis, were rare but have been reported.
What Do I Need to Know?
After training from your health care provider, you or your caregiver can use an autoinjector to give Dawnzera as a shot under the skin of your belly, thigh, or the back of your upper arm. The usual dose is once every four weeks, but if your condition is well controlled, your health care provider may consider switching to once every eight weeks.
